POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. www.vaers.hhs.gov to file a report, or call POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Hemoglobin Stability in the ASCEND-D and ND trials. Registered in England and Wales No. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. GSK Careers Apply POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. 2. A Population Study. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Ferguson GT, Brown N, Compton C, et al. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. ur employees and our values are at the heart of everything we do. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. 2. 5. Dransfield MT, Halpin DMG, Han MK, et al. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? Our employees and our values are at the heart of everything we do. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). www.fda.gov/medwatch. If you require an accommodation or other assistance to apply for a job at GSK, please contact the GSK Service Centre at 1-877-694-7547 (US Toll Free) or +1 801 567 5155 (outside US). Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de Today's top 149 Gsk Medical Affairs jobs in United States. 2018;22(6):527-545. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). 37 GSK Global Medical Affairs Lead jobs. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Silver J, Deb A, Packnett E, et al. 11. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. P1448. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) ? Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell?driven antitumor immunity. Assessment of Asthma Control in Respiratory Specialist Offices in the US. Bitte helfen Sie uns, Glassdoor zu schtzen, indem Sie besttigen, dass Sie 1. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. 13. The winners found large companies with a big Hispanic workforce and created solutions including an employer caregiver toolkit and caretaker programs. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Sansbury LB, Hinds D, Chao J, et al. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. POSTER: Knowledge of Invasive Meningococcal Disease and Vaccination Recommendations for Adolescents and Young Adults among US Physicians. 1. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Areas, Search Medical The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Poster No. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. You are using an unsupported browser.Some features of this site may not function properly. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. [Poster No. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) ? Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Reasons why patients with severe asthma discontinue biologic treatment. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. Blake SJ, Stannard K, Liu J, et al. Poster No. 4. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. 1. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. 2. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. P806; Abstract A4295]. 14. para nos informar sobre o problema. Further details on cookies and how to object to their placement can be found in our Cookie Policy. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. GSK values your privacy and your trust is important to us. P474; Abstract A3997]. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Asthma control among the treated U.S. asthma population in Practice Fusion?s Electronic Medical Record Research Database, 2015-2018. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. Cancer Cell.2019;36(1):100-114. * Works in partnership with country teams to create and then implement global medical . Bogart M, Chastek B, White J, et al. 3888792. 8. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. 3. [Poster No. Our market sites can be reached by visiting our location selector. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Gibbons D, Marijam A, Symons JM, et al. Moraes F, Abreu G, Nogueira T, et al. POSTER: Differentiation of Niraparib and Olaparib Brain Penetration in a Mouse Brain Metastatic Tumor, 4. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. (Poster No. Oral presentation. Insights From Allergy Practice (Poster No. CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion. Cookies will only be set if you choose to accept them. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK?859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. Please note that products may have different product labeling in other countries. 2. P372; Abstract A6482]. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS), 4. Ismaila A, Haeussler K, Czira A, et al. 336), 1. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. 2016;52:50-66. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. Bell CF, et al. (Poster No. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. Stability Calculator, Contact Poster No. 2. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. 2. Chandler R et al. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. The products discussed may have different product labeling in different countries. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. Learn how to prepare, what will be collected, and how to safely store your medicine until the event at: Tai Y-T, Anderson KC. GSK's Dr. Len Friedland, VP and Director of Scientific Affairs and Public Health for Sideline RSV Behind the science Oncology Gaining a deeper understanding of myelofibrosis - a rare blood cancer. Working closely with our employee resource groups, we launched the Accelerating Difference - Ethnic Diversity development program. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). POSTER: Subramanian S, et al. Immune checkpoints and their inhibition in cancer and infectious diseases. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. los inconvenientes que esto te pueda causar. We're committed to doing the right thing for the people who count on us, and our culture will help you deliver what matters most - better and faster. 3. P1446. Medical Affairs Gsk jobs. 10. GlaxoSmithKline. Eur J Cancer. McCormack E, Adams KJ, Hassan NJ, et al. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. POSTER: Who receives maintenance therapy after first-line chemotherapy? How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. A Population Study. Seo J, Zhang S, Krucien N, et al. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. Wechsler M, Kovalszki A, J Silver, et al. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations.